Researchers from Miguel Hernández University of Elche (UMH) in Spain have identified an effective strategy to reduce structural liver damage and improve hepatic vascular function in cirrhosis.

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may have disease modifying effects when used early in the course of disease.

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve durable disease control in the second-line setting while stopping daily ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

ITP is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting.

Aggressive cancers can use blood vessels like roadways, speeding through the body and finding new places to grow. But new ...

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

How Does Doptelet Work in Thrombocytopenia? Thrombocytopenia is when your blood has too few platelets (also called thrombocytes). Platelets are blood cells made in the soft, spongy tissue inside your ...

Wei Li, M.D., Ph.D., FAHA is an associate professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine in Huntington, West Virginia ...